Wellnex Life is the lead ASX “runner of the week” after its shares rise following an agreement to sell its Pain Away medicinal cream brand for up to $21.3 million. Multiple outlets report that the transaction is structured as a sale with potential value up to that figure, and that the company expects the proceeds to remove its debt. The coverage across newspapers highlights the same core development: the company’s announcement of the Pain Away brand sale and the market reaction that follows. Each source links the share movement to the prospect of becoming debt-free as a result of the deal. While the articles focus on Wellnex Life as the featured stock for the week, they do not provide additional, differing details in the supplied excerpts about the buyer, timing of completion, or specific conditions beyond the stated maximum sale price and the debt reduction outcome. Overall, the agreement to sell the Pain Away brand for up to $21.3 million is presented as the key catalyst behind the company’s stock performance.